Filament Brings Coca Leaves to Canada from Peru

Psilo Scientific, a subsidiary of Filament, will use the leaves to research neuropsychiatric applications.

Magdalena Biosciences, the joint venture between Filament Health (OTCQB: FLHLF) (NEO: FH) and Jaguar Health Inc., has imported coca leaves to Filament’s Vancouver, British Columbia, research facility.

The import, authorized by the Peruvian Health Authority and obtained from Peru’s only sanctioned coca distributor, Empresa Nacional de la Coca (ENACO), will be used in research on neuropsychiatric applications. The leaves are now under the care of Psilo Scientific, a subsidiary of Filament Health.

“This import is a significant achievement which validates the work of our regulatory team and affirms our ability to develop productive relationships with government agencies globally,” Filament CEO Benjamin Lightburn, who is also a Magdalena board member, said in a statement.

Both Magdalena and Filament Health are working toward full compliance with the Nagoya Protocol, an international agreement on the fair use of genetic resources and the recognition of indigenous and local communities’ traditional knowledge.

Magdalena Biosciences was established with a focus on developing plant-based medicines for mental health conditions. The recent coca leaf import is a part of their ongoing research initiatives.

“We appreciate Filament and Magdalena’s efforts to ensure that they have fully followed all of the requirements of ENACO, and that they are working through the process to obtain full compliance with the Nagoya Protocol in Peru,” said Richard Caballero, director of industrial commercialization at ENACO.

The news comes months after Canada moved to decriminalize the possession of small quantities of outlawed drugs including cocaine, methamphetamine, and ecstasy, as well as opioids such as heroin, fentanyl, and morphine.

British Columbia-based Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) announced earlier this year that it received a green light from the federal government to begin selling cocaine and psilocybin. Regulators at the time reiterated that sales would only be allowed to pharmacies, hospitals, and researchers.

Adam Jackson

Adam Jackson writes about the cannabis industry for the Green Market Report. He previously covered the Missouri Statehouse for the Columbia Missourian and has written for the Missouri Independent. He most recently covered retail, restaurants and other consumer companies for Bloomberg Business News. You can find him on Twitter at @adam_sjackson and email him at

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.